DNA treatment cuts bad cholesterol by nearly 50% without statins

Researchers have designed a new DNA-based treatment that targets PCSK9, a protein closely tied to high LDL cholesterol and atherosclerosis. Their most effective molecule reduced PCSK9 protein by 87% in human liver cells and lowered cholesterol by 47% in genetically modified mice after a single injection.

Officials and experts continue to monitor developments closely as the situation unfolds. Communities affected by the story are watching for further updates in the days ahead. Analysts say the implications could extend well beyond the immediate headlines, with policymakers and industry leaders expected to respond in the coming weeks.

Readers following this story should check back for the latest details as new information becomes available.